Markets:

Overview

News

Currencies

International

Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

12.89 -0.86 (-6.25%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neuropace, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data ↗

July 28, 2026

NeuroPace (NASDAQ:NPCE) said the U.S. Food and Drug Administration determined that its premarket approval supplement seeking to expand the RNS System indication to patients with medication-resistant...

Via MarketBeat

These stocks are moving in today's after hours session ↗

July 28, 2026

Via Chartmill

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

July 28, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

May 29, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace (NASDAQ:NPCE) Beats Q1 Estimates, Raises Full-Year Revenue Guidance ↗

May 12, 2026

Via Chartmill

NeuroPace Inc (NASDAQ:NPCE) Beats Q4 2025 Estimates and Reiterates 2026 Outlook ↗

March 03, 2026

Via Chartmill

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

May 29, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace (NPCE) Q1 2026 Earnings Transcript ↗

May 14, 2026

NeuroPace (NPCE) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Artificial Intelligence

NeuroPace Q1 Earnings Call Highlights ↗

May 12, 2026

NeuroPace (NASDAQ:NPCE) raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution...

Via MarketBeat

Topics Artificial Intelligence Earnings

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

May 12, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026

April 29, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

April 27, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference

April 10, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Present at the Leerink Global Healthcare Conference

March 05, 2026

From NeuroPace, Inc.

Via Business Wire

Why NeuroPace Stock Was Inching Higher on Wednesday ↗

March 04, 2026

The company finished 2025 with a convincing pair of earnings beats.

Via The Motley Fool

NeuroPace (NPCE) Q4 2025 Earnings Call Transcript ↗

March 03, 2026

NeuroPace (NPCE) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

March 03, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

February 20, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

January 13, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 31, 2025

From NeuroPace, Inc.

Via Business Wire

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

December 17, 2025

From NeuroPace, Inc.

Via Business Wire

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

December 08, 2025

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

December 02, 2025

From NeuroPace, Inc.

Via Business Wire

NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

November 24, 2025

From NeuroPace, Inc.

Via Business Wire

NeuroPace (NPCE) Q3 2025 Earnings Call Transcript ↗

November 09, 2025

NeuroPace (NPCE) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings World Trade

These stocks are moving in today's session ↗

November 05, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Keep an eye on the top gainers and losers in Wednesday's session. ↗

November 05, 2025

Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 05, 2025

Via Benzinga

Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗

November 05, 2025

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

November 05, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.